Previous 10 | Next 10 |
The 300 mg dose group will provide more information on the drug exposure vs adverse event relationship which is critical to FDA approval given the FDA’s Project Optimus Oncology initiative. P atients treated with Next Generation Chemotherapy-Capecitabine have NO...
Processa Pharmaceuticals (NASDAQ: PCSA) , the developer of the next-generation chemotherapy drugs that will provide a better safety-efficacy profile than widely used FDA-approved counterparts, will be presenting at the 33rd annual Oppenheimer Healthcare Conference, held on March 14, 2023. Accordi...
HANOVER, MD, March 07, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), the developer of the Next Generation Chemotherapy drugs that will provide a better safety-efficacy profile than their widely used FDA-approved...
Processa Pharmaceuticals (NASDAQ: PCSA) today reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next Generation Chemotherapies (“NGCs”). According to the update, previous studies with these NGCs suggest potential improvement in the sa...
Our Next Generation Chemotherapies ( NGC s ) are cancer treatments where the metabolism and/or distribution of an FDA-approved drug ha s been altered to provide potentially safer and more effective chemo t herapy to cance...
Processa Pharmaceuticals (NASDAQ: PCSA) , a diversified clinical-stage company developing next-generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient’s survival and/or quality of life, announced that it has ...
HANOVER, MD., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to...
Nanocap biopharma Processa Pharmaceuticals ( NASDAQ: PCSA ) shed ~10% for the fourth straight session on Friday after announcing agreements with retail investors to issue more than $6M of its common stock in a registered direct offering. Per the terms, more than 7.8M shares of the...
HANOVER, MD., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to...
Processa Pharmaceuticals (NASDAQ: PCSA) , a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present an update on Processa’s future therap...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...